Pfizer teams up with Alloy for antibody discovery Feb. 11, 2025 9:35 AM ET Pfizer Inc. (PFE) Stock By: Val Brickates Kennedy, SA News Editor 1 Comment Play (<1min) georgeclerk ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.&nbsp… ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.

The $1.7 billion in total new cuts come on top of a multibillion-dollar reorganization plan first unveiled in 2023. In October of that year, Pfizer laid out its intention to start an "enterprise ...

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three ...

In October 2023, Pfizer said it would move to cut $3.5 billion in costs by the end of 2024. Just two months later, the drugmaker added $500 million to the tally of planned cuts, for a total of $4 ...